Terms: = Lung cancer AND CD52, CDW52, EDDM5 AND Treatment
4 results:
1. Alemtuzumab clearance, lymphocyte count, and T-cell chimerism after hematopoietic stem cell transplant in sickle cell disease.
Furstenau D; Peer CJ; Hughes TE; Uchida N; Tisdale J; Hall OM; Figg WD; Hsieh M
Pharmacotherapy; 2022 Jan; 42(1):14-22. PubMed ID: 34669981
[TBL] [Abstract] [Full Text] [Related]
2. cd52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies.
Remon J; Abedallaa N; Taranchon-Clermont E; Bluthgen V; Lindsay CR; Besse B; Thomas de Montpréville V
Lung Cancer; 2017 Jun; 108():168-172. PubMed ID: 28625631
[TBL] [Abstract] [Full Text] [Related]
3. Soluble cd52 is an indicator of disease activity in chronic lymphocytic leukemia.
Vojdeman FJ; Herman SEM; Kirkby N; Wiestner A; van T' Veer MB; Tjønnfjord GE; Itälä-Remes MA; Kimby E; Farooqui MZ; Polliack A; Wu KL; Doorduijn JK; Alemayehu WG; Wittebol S; Kozak T; Walewski J; Abrahamse-Testroote MCJ; van Oers MHJ; Geisler CH; Niemann CU
Leuk Lymphoma; 2017 Oct; 58(10):2356-2362. PubMed ID: 28278728
[TBL] [Abstract] [Full Text] [Related]
4. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H.
Hutchins JT; Kull FC; Bynum J; Knick VC; Thurmond LM; Ray P
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):11980-4. PubMed ID: 8618827
[TBL] [Abstract] [Full Text] [Related]
